Uncategorized
Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist peptide. It is structurally modified to prolong systemic exposure via albumin binding.
$69.99
Free shipping
Free Damage Protection
Secure checkout
Research Applications
Third Party Tested by Freedom Diagnostics
Study of dual incretin signaling pathways
Evaluation of glycemic control mechanisms
Investigation of weight reduction and appetite regulation
Analysis of beta-cell function and insulin secretion
Technical Information
Technical specifications
Product Specifications
Molecular class
Synthetic peptide analog
Mechanism
GLP-1 + GIP receptor agonism
FDA Status
Approved
🧊 Storage Requirements
Handling Information
Protect from light
Refrigerated
2-8°C
Potential Benefits
Based on findings from clinical trials, researchers are exploring several potential benefits:
Significant Weight Loss
Clinical trials have shown that patients using tirzepatide can achieve substantial weight reduction, with some studies reporting average losses ranging from 15% to over 20% of total body weight depending on the dosage and trial duration. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide:
⚠️ Compliance
Approved medication; research use follows clinical labeling unless otherwise specified